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Background: Plasmablastic lymphoma (PBL) is a rare aggressive neoplasm with lymphoid and plasmacytic
differentiation that is commonly associated with immunodeficiency and an unfavorable prognosis. Clinicopathologic
features have been largely derived from cases reports and small series with limited outcome analyses.
Patients and methods: The demographic, clinicopathologic features, and clinical outcomes of a cohort of 61 patients
with PBL were reviewed and analyzed.
Results: Patients had a median age of 49 years (range 21–83 years) and most (49/61; 80 %) were men. Human
immunodeficiency virus (HIV) status was available for 50 patients: 20 were HIV-positive and 30 HIV-negative. Twenty-three
patients were immunocompetent. Abdominal/gastrointestinal complaints were the most common presenting symptoms,
reported in 14 of 47 (30 %) of patients. At presentation, 24 of 43 (56 %) patients had stage III or IV disease. Epstein-Barr
virus (EBV) was detected in 40 of 57 (70 %) cases. MYC rearrangement was identified in 10/15 (67 %) cases assessed, and
MYC overexpression was seen in all cases assessed regardless of MYC rearrangement status. HIV-positive patients were
significantly younger than those who were HIV-negative (median 42 vs. 58 years; p = 0.006). HIV-positive patients were also
significantly more likely to have EBV-positive disease compared with HIV-negative patients (19/19, 100 % vs. 15/29, 52 %;
p = 0.002). Patients who received CHOP chemotherapy tended to have better overall survival (OS) compared
with those who received hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone
(hyper-CVAD) (p = 0.078). HIV status had no impact on OS. Patients with EBV-positive PBL had a better event-free
survival (EFS) (p = 0.047) but not OS (p = 0.306). Notably, OS was adversely impacted by age ≥50 years (p = 0.013),
stage III or IV disease (p = <0.001), and lymph node involvement (p = 0.008).
Conclusions: The most significant prognostic parameters in patients with PBL are age, stage, and, to a lesser extent,
EBV status. In this study, two-thirds of PBL cases assessed were associated with MYC rearrangement and all showed
MYC overexpression.
Keywords: Plasmablastic lymphoma, EBV, HIV, Immunodeficiency, Immunocompetent, MYC* Correspondence: jkhoury@mdanderson.org
†Equal contributors
1Department of Hematopathology, The University of Texas, M.D. Anderson
Cancer Center, 1515 Holcombe Boulevard, MS-072, Houston, TX 77030, USA
Full list of author information is available at the end of the article
© 2015 Loghavi et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Loghavi et al. Journal of Hematology & Oncology  (2015) 8:65 Page 2 of 11Introduction
Plasmablastic lymphoma (PBL) is a rare type of non-
Hodgkin lymphoma in which the neoplastic cells are
postulated to arise from plasmablasts, defined as short-lived
B cells that have switched their transcriptional phenotype
to a plasma cell gene expression program [1]. Under
physiologic conditions, sensitized memory B cells activated
by repeated exposure to antigen can differentiate
within approximately 7 days into plasmablasts capable
of immunoglobulin heavy chain (IgH) class switching
[2]. While the canonical immunophenotype of such
plasmablasts is CD19low/CD20−/CD38high/CD138−/+,
an intermediate CD20+ pre-plasmablast phase has been
identified [2, 3]. Notably, infection by human immuno-
deficiency virus (HIV) and Epstein-Barr virus (EBV), or
both, are known to cause an unusual surge in plasmablast
levels in the blood and lymph nodes.
Although PBL commonly occurs in HIV-positive
individuals, it may also arise in association with other
immunodeficiency or immunocompromised states such as
organ transplantation, autoimmune diseases, and older age,
as well as in immunocompetent individuals. Among HIV
patients, PBL constitutes an acquired immunodeficiency
syndrome (AIDS)-defining condition. Currently, PBL
is defined as a high-grade lymphoma comprised of a
diffuse proliferation of large neoplastic cells that resemble
immunoblasts or plasmablasts expressing an immunophe-
notype resembling that of plasma cells [1, 4].
The scope of clinicopathologic features and outcomes
of patients with PBL remains poorly characterized, in
large part due to the rarity of this entity whose fea-
tures have been largely pieced together through case
reports and small case series. In a recent study in
which Morscio et al. assessed 28 cases of PBL from
their institution and performed a literature review,
they suggested a framework for categorizing PBL patients
into three broad categories: (1) HIV-positive, (2) immuno-
competent, and (3) post-transplantation [5]. In this study,
we build on this proposed framework and analyze the
clinicopathologic features, therapeutic approaches, and




Most patients were men (80 %) with a median age of
49 years (range 21–83 years). The most common pre-
senting symptoms included abdominal/gastrointestinal
complaints (e.g., diarrhea, hematochezia, pain) (14/47;
30 %), localized mass or swelling (12/47; 26 %), and
oral/nasal symptoms (e.g., ulcer, epistaxis, rhinorrhea,
sinusitis) (8/47; 17 %). Lymph node involvement was
identified in 34 of 49 (69 %) patients. Extranodal disease
was relatively common, with the oral/nasal cavity (21/46;46 %) and gastrointestinal tract (12/60; 20 %) being the
most commonly involved extranodal sites. Among
patients with available staging information, 19/43 (44 %)
presented with Ann Arbor stage I/II disease and 24/43
(56 %) presented with stage III/IV disease.
Patients were divided into four clinical categories:
HIV-positive (PBL-HIV) (n = 20), post-transplant (PBL-PT)
(n = 3), autoimmune disease (PBL-AD) (n = 4), and
immunocompetent (PBL-IC) (n = 23) (Table 1). Excluded
from these categories (and thus analyses of clinical
features) are 11 patients for whom HIV status was
not available. Patients in the PBL-HIV category were
significantly younger (median 41.7 vs. 57.8 years; p = 0.006)
than patients in other categories. All PBL-HIV cases
assessed were EBV-positive compared with 52 %
among cases arising in patients within other categories
(19/19 vs. 15/29; p = 0.002). Receipt of combined
antiretroviral therapy (cART) was documented for 17
HIV-positive patients; no data regarding cART therapy
was available for the remaining 3 patients.
Patients in the PBL-PT category included one patient
(case 2) who had received allogeneic SCT for accelerated
chronic lymphocytic leukemia/small lymphocytic lymph-
oma (CLL/SLL) 7 years prior to developing PBL and two
patients (cases 1 and 15) who had received liver transplants.
Patients in the PBL-AD category included one patient with
rheumatoid arthritis, one with ulcerative colitis, one with
Crohn disease, and one with Sjögren syndrome. Patients in
the PBL-IC group had no apparent evidence of immuno-
deficiency and were by default regarded as immunocompe-
tent. Since no agreed upon cutoff exists for age-related
decline in immunocompetence, patients were not grouped
a priori on the basis of age. Cutoffs of 50 and 60 years were
assessed for prognostic significance, and both were found to
be associated with overall survival (OS) (see below).
Five patients in our study group had a history of lymph-
oid malignancy. One patient with CLL/SLL was mentioned
above. Two patients (cases 30 and 48) had a history of dif-
fuse large B cell lymphoma (DLBCL), and one patient (case
29) had a history of Burkitt lymphoma. One of the patients
with DLBCL (case 30) and the patient with Burkitt lymph-
oma were HIV-positive. Interestingly, the former patient
(case 30) developed PBL with t(8;14)(q24.1;q32) and MYC/
IGH rearrangement 8 years following therapy for DLBCL
(Fig. 1e, f). The second patient with DLBCL (case 48) had a
composite lymphoma consisting of a conventional DLBCL
and PBL, each component with typical morphology and
immunophenotype. The fifth patient (patient 34) had a
remote history of lymphoma according to the clinical notes;
the original lymphoma was not available to us for review.
Histopathologic features
An incisional/excisional biopsy specimen was obtained in
41 (67 %) patients, needle biopsy in 18 (30 %) patients,
Table 1 Clinical features of plasmablastic lymphoma patients in this study group
Total PBL-HIV PBL-PT PBL-AD PBL-IC p value p value p value
N (%) N (%) N (%) N (%) N (%) (HIV vs. IC) (HIV vs. other) (IC vs. other)
Patientsa 61 (100) 20 (33) 3 (5) 4 (7) 23 (38)
Age 0.026 0.006 0.141
Median (years) 49.2 41.7 66 52 55.7
Range (years) 21–83 30–63 29.1–73.0 38–76 26–81
Sex 0.075 0.092 0.073
Male 49 (80) 19 (95) 2 (67) 3 (75) 18 (78)
Female 12 (20) 1 (5) 1 (33) 1 (25) 5 (22)
Race 0.362 0.275 0.203
Caucasian 33 (54) 11 (55) 3 (100) 1 (25) 12 (52)
Hispanic 9 (15) 2 (10) 1 (25) 5 (22)
Black 2 (3) 2 (10) 0
Asian 7 (12) 2 (10) 1 (25) 3 (13.0)
Unspecified 10 (16) 3 (15) 1 (25) 3 (13.0)
Site(s) of involvementb 0.469 0.526 0.406
Nasal/oral cavity 21/46 (46) 9 (45) 6 (26)
Lymph node 34/49 (69) 14 (70) 1/1 (100) 1/2 (50) 13/21 (62)
GI tract 12 (20) 3 (15) 1(33) 3 (75) 3 (13.0)
Bone 7 (12) 4 (20) 3 (13.0)
Bone marrow 8/44 (18) 1/18 (6) 1 (33) 1/3 (33) 4/18 (22)
Abdominal/pelvic cavity 6 (10) 2 (10) 1 (33) 1 (25) 2 (9)
Body fluid 6 (10) 1 (5) 1 (33) 2 (9)
Liver 2 (3) 1 (5) 1 (25)
Skin 2 (3)
Soft tissue 2 (3) 2 (9)
Retroperitoneum 2 (3) 1 (5) 1 (33)
Mediastinum 2 (3) 1 (4)
Tonsil 1 (2) 1 (4)
Testis 1 (2) 1 (4)
Penis 1 (2) 1 (4)
Spleen 1 (2) 1 (5)
Gynecologic organs 1 (2) 1 (5)
Breast 1 (2) 1 (4)
Bladder 1 (2) 1 (4)
Kidney 1 (2) 1 (5)
NA 1 (2) 0
Ann Arbor stage at diagnosis 0.979 0.577 0.619
I + II 19/43 (44) 4 (20) 1 (25) 6 (26)
III + IV 24/43 (56) 3 (15) 1 (25) 4 (17)
Chemotherapy 0.495 0.431 0.889
H-CVAD 16/42 (38) 5 (25) 1 (33) 2 (50) 8 (50)
CHOP 8/42 (19) 4 (20) 1 (33) 3 (13)
EPOCH 7/42 (17) 4 (20) 1 (33) 1 (25) 1 (4)
Other 11/42 (26) 1 (5) 1 (25) 6 (14)
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Table 1 Clinical features of plasmablastic lymphoma patients in this study group (Continued)
Radiation therapy 18/41 (44) 5/15 (33) 1 (33) 0/3 11/18 (61)
Stem cell transplant 6/42 (14) 1/15 (7) 1 (33) 0/3 4/19 (21)
Survival (months) 0.198 0.500 0.184
Median 7 14 35 2 17
Range 0.3–156 0.3–120 9–156 1–7 0.2–150
Status at last follow-up
Dead 43 (71) 15 (75) 3 (100) 2 (50) 6 (26)
Alive 18 (30) 5 (25) 0 2 (50) 17 (74)
PBL plasmablastic lymphoma, HIV human immunodeficiency virus, PT post-transplant, AD autoimmune disease, IC immunocompetent, EPOCH etoposide,
prednisone, vincristine, cyclophosphamide, doxorubicin, CHOP cyclophosphamide, doxorubicin, vincristine, prednisone, H-CVAD hyperfractionated cyclophosphamide,
vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, NA not available
aHIV status for 11 patients was unknown
bSome patients had more than one site of involvement; therefore, the cumulative data may exceed 100 %
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bone marrow aspiration and biopsy in 1 (2 %) patient.
Morphologic evaluation was limited in a small subset
of cases due to limited material, extensive necrosis,
and/or crush artifact. All cases had a diffuse growth
pattern. A “starry-sky” pattern was seen in 22 cases and
necrosis in 14 cases. The neoplastic cells exhibited
exclusively plasmablastic morphology in 52 cases, whereas
in 4 cases they consisted of an admixture of plasmablasts
and plasmacytic cells. Large, pleomorphic multinucleated
cells were identified in six cases.
Immunophenotyping and colorimetric in situ
hybridization results
Colorimetric in situ hybridization for EBV-encoded RNA
(EBER) was positive in 40/57 (70 %) cases. Among cases
assessed for immunoglobulin light chain expression, 45/52
(87 %) expressed cytoplasmic light chain: 28 kappa and 17
lambda. The neoplastic cells were also positive for the
following antigens: CD138 (54/58; 93 %); MUM1 (22/24;
92 %); CD38 (10/13; 77 %); CD45 (20/40; 50 %); CD79a
(13/35; 37 %); CD10 (13/32; 41 %); CD56 (12/37; 32 %);
BCL2 (5/20; 25 %); CD43 (5/19; 26 %); epithelial
membrane antigen (EMA) (5/16; 31 %); BCL6 (4/22;
18 %); CD15 (1/7; 14 %); CD30 (5/38; 13 %); PAX5 (4/32;
13 %); and CD3 (5/51; 10%, mostly focal, weak). Two cases
were assessed for CD117 and both were positive. Cyclin
D1 was focally positive in 1/15 (7 %) cases. All cases
assessed were negative for CD20 (n = 60), and HHV8 (n =
33). Ki-67 was assessed in 43 cases demonstrating a me-
dian Ki-67 proliferation index of 90 %. A summary of the
immunophenotypic features of PBL in patients within
various clinical categories is provided in Table 2 and
further illustrated in Fig. 2.
Conventional cytogenetics and fluorescence in situ
hybridization results
Conventional cytogenetic analysis results were avail-
able for 13 cases, of which 5 had clonal chromosomalabnormalities (Additional file 1: Table S1), 7 had a diploid
karyotype, and 1 had abnormal non-clonal metaphases
with numerical and structural changes. Abnormalities of
chromosome 8 were identified in 4 cases including 2 cases
with t(8;14)(q24;q32).
Fluorescence in situ hybridization (FISH) using probes
specific for the MYC locus was performed on 15 cases, of
which 10 (67 %) were positive for MYC gene rearrange-
ment. Notably, there was no significant association
between MYC rearrangement and clinical categories. We
performed immunohistochemistry to assess MYC protein
expression in a subset of cases with (n = 10) and without
(n = 3) available MYC status by FISH and/or conventional
karyotyping for which tissue was available. All cases
assessed showed of MYC overexpression regardless of
MYC rearrangement status. However, the extent (median
90 % positive nuclei; range 60–100 % vs. median
75 % positive nuclei; range 60–100 %) and intensity
(3+ vs. 2+) of MYC overexpression were more pronounced
in cases with MYC rearrangement (n = 6) compared with
those withoutMYC rearrangement (n = 4).
Horn et al. recently reported that CD10 expression is
more commonly seen in diffuse large B cell lymphomas
with immunoblastic morphology and MYC rearrange-
ments compared with cases with intact MYC [6]. Ac-
cordingly, we asked whether such a correlation might
hold true for PBL, particularly in view of the seemingly
consistent presence of MYC overexpression in this dis-
ease. Interestingly, there was no significant difference
in CD10 expression between cases with and without
MYC rearrangement in the small group of PBL cases
we were able to assess (3/7; 43 % vs. 1/4; 25 %, re-
spectively; p = 1.000).
Treatment
Treatment details were available for 42 (69 %) patients,
of whom 3 did not receive any form of therapy for PBL.
Six patients had a history of having received therapy for
PBL, but further details were not available. Treatment
Fig. 1 Representative case of plasmablastic lymphoma. a Neoplastic cells have plasmablastic morphology, with a prominent nucleolus and
moderate amount of cytoplasm. Mitotic figures and tingible-body macrophages are abundant and impart a “starry-sky” pattern (H&E, ×200).
b The neoplastic cells are diffusely positive for EBV-encoded RNA (EBER) by colorimetric in situ hybridization (×200). c CD20 expression is
absent. This case was negative for CD19 and positive for CD38 by flow cytometry (data not shown) (×200). d MYC overexpression is positive by
immunohistochemistry (×200). e Karyotype of case 30 (nasopharyngeal mass): 46, XY, del(6)(q23q29),t(8;14)(q24;q32), add(20)(p13). f Fluorescence in
situ hybridization using a dual-color break-apart probe specific for the MYC locus on formalin-fixed paraffin-embedded tissue (case 30) showing split
signals in ~80 % of nuclei (circle: fusion signal; arrow: split signal)
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whom therapy details were available were as follows: 16
(48 %) patients received chemotherapy alone, 17 (52 %)
received chemotherapy and radiation therapy, and 1 patient
(3 %) received radiation therapy alone. Subsequently, 6
(18 %) patients underwent autologous SCT (4 following
chemotherapy and radiation therapy; 2 following chemo-
therapy alone). One patient underwent allogeneic SCT
6 months after relapse following autologous SCT.
Chemotherapy regimens used are summarized in
Table 1. They included hyperfractionated cyclophos-
phamide, vincristine, doxorubicin, and dexamethasone(hyper-CVAD) (15/33; 45 %); CHOP (7/33; 21 %);
etoposide, vincristine, doxorubicin, cyclophosphamide, and
prednisone (EPOCH) (7/33; 21 %); and CHOP followed
by hyper-CVAD (1/33; 3 %). Two patients received
vincristine and prednisone, and one patient received
cyclophosphamide, vincristine, and prednisone (CVP).
Outcome analysis
The median follow-up duration was 7 months (range,
0.3–156 months). At last follow up, 43 (71 %) of PBL
patients were dead and 18 (30 %) were alive. Among
patients who received therapy, 19/39 (49 %) achieved
Table 2 Summary of immunophenotypic features and MYC rearrangement status
Total N (%) PBL-HIV N (%) PBL-PT N (%) PBL-AD N (%) PBL-IC N (%)
CD10 13/32 (41) 6/14 (43) 1/2 (50) 1/2 (50) 3/10 (30)
CD20 0/60 0/20 0/3 0/4 0/23
CD45 20/40 (50) 6/11 (54) 0/1 0/2 7/18 (39)
CD56 12/37 (32) 4/11 (36) 0/3 1/3 (33) 5/15 (33)
CD79a 13/35 (37) 2/11 (18) 0/1 1/3 (33) 6/13 (46)
CD138 54/58 (93) 15/19 3/3 (100) 4/4 (100) 22/23 (96)
MUM1 22/24 (92) 8/8 (100) 2/2 (100) 3/4 (75) 7/8 (88)
MYC 13/13 (100) 7/7 (100) 1/1 (100) 0/0 (0) 4/4 (100)
Ki-67 (% median) 90 87.5 97.5 90 80
EBER (ISH) 40/57 (70) 19/19 (100)* 1/3 (33) 2/4 (50) 12/22 (55)
MYC rearrangement (FISH) 10/15 (67) 5/7 (71)** 1/1 (100) NA 3/6 (50)
PBL plasmablastic lymphoma, HIV human immunodeficiency virus, PT post-transplant, AD autoimmune disease, IC immunocompetent, EBER Epstein- Barr
virus-encoded RNA, ISH in situ hybridization; FISH fluorescence in situ hybridization, NA not available
*p = <0.001 (PBL-HIV vs. others); **p = 0.323 (PBL-HIV vs. others)
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patient who died of a cardiac cause, were alive at last
follow up. On the other hand, 14/39 (36 %) patients
had persistent disease, and 11 of these were dead at
last follow up.
Overall survival (OS) was more favorable for pa-
tients <50 years of age compared with those ≥50 years
(p = 0.013) (Fig. 3a). A similar finding was identified using
60 years as a cutoff (p = 0.001). Whereas involvement of
visceral organs did not impact OS (p = 0.759), lymph node
involvement was associated with a significantly worse OS
(p = 0.008) (Fig. 3b). In addition, patients who pre-
sented with stage I/II disease had more favorable OS
and event-free survival (EFS) compared to those who
presented with stage III/IV disease (p = <0.001 and
0.001, respectively) (Fig. 3c, d). Bone marrow involvement
was also associated with a worse OS and EFS (p = 0.033
and 0.016, respectively). When we compared the OS of
patients who received CHOP alone to those who received
only hyper-CVAD, the former tended to have a better
OS, although the difference did not attain statistical
significance (p = 0.078). EBV-positive status was asso-
ciated with a better EFS compared to EBV-negative
status for the entire patient cohort (p = 0.047) as well
as patients <60 years (p = 0.015). No association between
EBV status and OS was identified (p = 0.306). HIV status
(p = 0.538), autoimmune disease (p = 0.235), transplant
history (p = 0.921), and oral/nasal cavity involvement
(p = 0.744) had no impact on OS. By multivariate analysis
using Cox regression modeling, age was independently
associated with OS (HR 1.191; 95 % CI 1.023–1.388;
p = 0.024). Although advanced stage, EBV status, and
HIV status were associated with an elevated hazards
ratio, they were not independently associated with OS
(Additional file 1: Table S2).Discussion
Plasmablastic lymphoma is an uncommon type of
non-Hodgkin lymphoma with overlapping features of
lymphoma and plasma cell neoplasms [7–9]. Although
earlier studies described neoplasms that, in retrospect,
were likely examples of PBL [10], it was not until
1997 that PBL was recognized as a distinct entity. At
that time, Delecluse et al. described 16 patients who
had aggressive B cell lymphoma with plasmacytic dif-
ferentiation characterized clinically by a predilection
for the oral cavity and a high association with both
HIV and EBV infection [11]. Many case reports and
small case series have since been published, and the
concept of PBL has been expanded to include similar
tumors in non-oral sites arising in patients with other
forms of immunodeficiency (HIV-negative) as well as
immunocompetent patients [12, 13].
The high association of PBL with immunosuppression,
oral cavity involvement, male gender, EBV infection, and
aggressive clinical behavior [14] has been traditionally
stressed in the literature. Several of these features were
identified in our study group. The prevalence of oral/
nasal involvement in the HIV-positive patients in our
group was comparatively high (45 %), similar to findings
reported by others [5, 13, 15]. In addition, EBV infection
was also common (70 %) in our study group, with
the highest relative incidence being in the PBL-HIV
group as noted previously [5, 13]. However, our study
group differed from other cohorts [13] in terms of
having a comparatively low (20/50; 40 %) prevalence of
HIV-positive patients.
There is no consensus yet regarding the optimal thera-
peutic approach for patients with PBL. Combination
chemotherapy is commonly used, in addition to cART for
HIV-positive patients. The current National Comprehensive
Fig. 2 Schematic representation of the immunophenotypic features of plasmablastic lymphoma cases in this study
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chemotherapy regimens such as CODOX-M/IVAC
(cyclophosphamide, vincristine, doxorubicin, high-dose
methotrexate alternating with ifosfamide, etoposide,
and high-dose cytarabine), dose-adjusted EPOCH, or
hyper-CVAD [16]. This is based primarily on data derived
from case reports and small case series. In addition,
regimens similar to those used to treat plasma cell
myeloma that incorporate bortezomib and consolida-
tion with high-dose chemotherapy followed by autolo-
gous stem cell transplant have been suggested [17].
Castillo et al. recommended recently frontline EPOCH
(+/− bortezomib) with intrathecal prophylaxis during each
cycle of EPOCH followed by consolidative high-dose
chemotherapy and autologous SCT in first remission, if
possible [13]. In our study, intensive chemotherapy showedsimilar or even worse results due to treatment-related
complications compared with CHOP, in line with results
identified in other studies [15, 18]. In addition, there was
no apparent benefit of hyper-CVAD-based therapy over
other regimens on EFS and OS (p = 0.186, p = 0.404). On
the other hand, the number of PBL patients in our study
group who received autologous SCT is too small to draw
any conclusions.
The outcome of PBL patients in this study was similar
to that reported by others, with a median OS of 6.5 months
[5, 19]. Favorable prognostic factors documented in the
literature include low stage, achieving clinical remission
with chemotherapy, age <60 years, oral location, and
absence of MYC/IGH gene rearrangement [12]. Our
univariate analysis showed that age <60 years and low
stage were associated with better OS. Although the use of
Fig. 3 Overall survival of plasmablastic lymphoma patients showing a significant adverse impact of age >50 years (a) and lymph node
involvement (b). Patients who presented with Ann Arbor stage III or IV disease had worse overall (c) and event-free survival (d) compared to
patients who presented with stage I or II
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improve outcomes among PBL patients [15], our findings
and those of others have not been able to confirm the
prognostic value of cART [20]. Additionally, in contrast
to previous reports, we were unable to confirm the detri-
mental effect of MYC gene rearrangements in our patient
cohort [5, 13, 20].
Immunophenotyping plays an important role in estab-
lishing a diagnosis of PBL. The neoplastic cells are
commonly positive for CD138, MUM1, and CD38,
and they are negative for CD45, CD20, and PAX5.
Cytoplasmic immunoglobulins are expressed commonly
[1]. However, the immunophenotypic profile of PBL is
variable. Four cases in our series were negative for CD138.
In these cases, the diagnosis of PBL was supported by
additional markers such as MUM1, monotypic cytoplas-
mic immunoglobulin light chain expression, and EBER
positivity combined with negativity for CD20 and PAX5.Additional markers including PRDM1/BLIPM1 and XBP1s
have also been shown to be helpful in identifying a plasma-
blastic immunophenotype [21]. As described by others [14],
CD10 expression (typically absent in normal plasma cells)
was detected in a sizeable subset of cases (13/32; 41 %) in
our study group.
It is essential to exclude other neoplasms whose clinical,
morphologic, or immunophenotypic features might overlap
with PBL. Such differential diagnostic considerations
include anaplastic (or pleomorphic) plasma cell myeloma,
extramedullary plasmacytoma (anaplastic, plasmablastic,
and plasmacytic), DLBCL with plasmacytoid differentiation,
anaplastic lymphoma kinase (ALK)-positive large B
cell lymphoma, extracavitary or solid variant of primary
effusion lymphoma (PEL), DLBCL associated with HHV8-
positive multicentric Castleman disease, and EBV-positive
plasmacytoma in immunocompetent patients (EPIC).
Patients with plasma cell myeloma usually have elevated
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evidence of end-organ damage, and their neoplastic cells
are rarely positive for EBV. Eight PBL patients in this
series had bone marrow involvement in addition to
systemic disease. All those tested were negative for serum
paraprotein. It is noteworthy that there is no consensus in
the literature regarding the utility of serum or urine para-
protein in distinguishing PBL from plasma cell myeloma,
and some reported patients with PBL had an M-protein
[14]. Another important entity in the differential diag-
nosis of PBL is DLBCL with plasmacytoid differentiation
wherein the absence of immunosuppression and lack of
EBV infection are much more common than in PBL. ALK
expression defines a form of DLBCL that often can exhibit
plasmablastic features. The presence of ALK expression
by immunohistochemistry and the identification of ALK
gene rearrangement typically establish the diagnosis of
ALK-positive large B cell lymphoma. Extracavitary/solid
variant of PEL can closely resemble PBL, but these
tumors by definition are positive for the HHV8 virus
[22–26]. DLBCL arising in HHV8-associated multicentric
Castleman disease is similarly positive for HHV8 by
definition [27]. The distinction between plasmablastic and
anaplastic plasmacytoma and PBL is challenging. Similar
to PBL, extramedullary plasmacytoma in general also
frequently involves the head-and-neck region but,
unlike PBL, only rare cases have been reported to be
EBV-positive. The latter, recently termed EPIC, arise
in the head-and-neck region or the gastrointestinal
tract in immunocompetent patients [28]. EPIC lesions are
composed of mature-appearing plasma cells. Unlike PBL,
they lack a “starry-sky” pattern or cytologic atypia and
often have a brisk CD8-positive cytotoxic T cell infiltrate
in the background.
In summary, PBL is a rare neoplasm with variable clinical
presentation and pathologic characteristics. Our study
shows a higher frequency of primary extranodal involve-
ment, HIV-negative status, and response to CHOP chemo-
therapy than has been commonly underscored in the
literature. Our findings suggest that younger patients with




We retrospectively identified patients diagnosed with PBL
at our institutions (UTMDACC and NUS) between 1994
and 2013. Most cases were submitted in consultation or
referred to our institutions after a biopsy was performed.
All biopsy specimen slides were reviewed as a part of this
study. Relevant clinical data including age at diagnosis,
sex, HIV status, medical history, disease sites, Ann Arbor
stage, therapies, and clinical outcomes were obtained from
medical records. Patients with a history of plasma cellmyeloma (PCM) were excluded from this study. This
study was approved by the Institutional Review Board of
The University of Texas M.D. Anderson Cancer Center in
accordance with the Declaration of Helsinki.
Immunohistochemistry and in situ hybridization
Immunohistochemical studies were performed on
formalin-fixed, paraffin-embedded tissue sections using
standard methods. The antibodies and dilutions used
were as follows: CD3 (1:100), CD19 (1:100), CD20
(1:1400), CD43 (1:100), CD45 LCA (1:300), CD79a
(1:50), CD117 (1:100), CD138 (1:600), MUM1 (1:35),
kappa (1:20,000), lambda (1:20,000), and Ki-67 (1:100)
(Dako, Carpinteria, CA); CD4 (1:80), CD10 (1:50), CD38
(1:75), EMA (1:600), BCL6 (1:40), and HHV8 (1:50)
(Leica Microsystems, Buffalo Grove, IL); CD5 (1:20) and
cyclin D1 (1:40) (Thermo Fisher, Fremont, CA); CD56
(1:100) (Life Technologies, Grand Island, NY); CD30
(1:80) (Covance, Emeryville, CA); MYC (1:50) (Ventana
Medical Systems, Tucson, AZ); and PAX5 (1:35) (BD
Bioscience, San Jose, CA).
In situ hybridization (ISH) for EBV-encoded small
RNA (EBER) was performed using a fluorescein-labeled
peptide nucleic acid probe (Dako) in conjunction with
the Dako peptide nucleic acid ISH detection kit for
formalin-fixed, paraffin-embedded tissue sections.
Karyotyping and fluorescence in situ hybridization
Conventional G-band karyotype analysis was per-
formed using standard methods as described previously
[29, 30]. Karyotypes were reported according to the
2013 International System for Human Cytogenetic
Nomenclature [31]. Fluorescence in situ hybridization
(FISH) was performed on formalin-fixed, paraffin-
embedded tissue sections as described previously [32].
Assessment for MYC rearrangement was performed using
LSI MYC dual-color break-apart probe (Abbot/Vysis,
Downers Grove, IL, USA), following the manufacturer’s
instructions. Signals were analyzed using a fluorescent
microscope (Carl Zeiss, Thornwood, NY). The cutoff for
MYC gene rearrangement in our laboratory is >3.8 %
nuclei with positive (break-apart) signals; however, all
positive PBL cases in this study had numerous cells with
positive signals, well above the cutoff level.
Statistical analysis
Survival was estimated by the Kaplan-Meier method.
Overall survival (OS) was calculated from the date of
diagnosis until death from any cause or last follow-up
date. Event-free survival (EFS) was calculated from the
date of diagnosis to the first event (disease progression or
relapse). Survival curves were compared by the log-rank
test. Differences between groups were considered signifi-
cant if P values were less than 0.05 in two-tailed test.
Loghavi et al. Journal of Hematology & Oncology  (2015) 8:65 Page 10 of 11Multivariate analysis was performed by Cox proportional
regression model to examine the relationship between
survival time and patient characteristics.
Key message
Plasmablastic lymphoma is a rare neoplasm with lymphoid
and plasmacytic differentiation that arises commonly, but
not exclusively, in immunocompromised patients. HIV
status has no impact on overall survival. The most signifi-
cant prognostic parameters include age, stage, and EBV
status. MYC deregulation is very common in PBL.
Additional file
Additional file 1: Table S1. Karyotypic abnormalities identified by
conventional cytogenetics in plasmablastic lymphoma cases. Table S2.
Cox regression analysis results.
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